Coherus Oncology
CHRS
146 hedge funds and large institutions have $98.5M invested in Coherus Oncology in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 62 increasing their positions, 42 reducing their positions, and 20 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
2.16% less ownership
Funds ownership: 47.74% → 45.59% (-2.2%)
8% less funds holding
Funds holding: 158 → 146 (-12)
19% less capital inflows, than outflows
Capital inflows: $9.42M | Capital outflows: $11.6M
35% less call options, than puts
Call options by funds: $136K | Put options by funds: $209K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.67M |
| 2 |
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust
Fort Myers,
Florida
|
+$1.24M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$921K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$811K |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$455K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.19M |
| 2 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$2.41M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$844K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$616K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$526K |
CHRS Hedge Fund Activity: Q2 2026 in Review
146 of the 8,351 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2026, worth a combined $98.5M — down 18% from $121M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CHRS and 10 opened new positions — a net loss of 10 holders — while 42 trimmed existing stakes and 62 added.
The largest buyer was BlackRock, adding an estimated $2.67M. The largest seller was Tang Capital Management, exiting entirely with an estimated $3.19M sold.
- 146 institutional investors held Coherus Oncology (CHRS) as of Q2 2026, down from 158 in Q1 2026.
- Funds reported $98.5M of Coherus Oncology stock for Q2 2026, down 18% quarter-over-quarter.
- 10 funds opened new Coherus Oncology positions in Q2 2026 and 20 closed out, a net change of -10 holders.
- The largest Coherus Oncology buyer in Q2 2026 was BlackRock, an estimated $2.67M added.
- The largest Coherus Oncology seller in Q2 2026 was Tang Capital Management, an estimated $3.19M sold.
Based on aggregated 13F filings for Q2 2026.